Biosynthesis of trialkyl-substituted aromatic polyketide NFAT-133 involves unusual P450 monooxygenase-mediating aromatization and a putative metallo-beta-lactamase fold hydrolase

Ming Yang,Wanlu Li,Lin Zhou,Xiao Lin,Wenyu Zhang,Yaoyao Shen,Hai Deng,Hou-wen Lin,Yongjun Zhou
DOI: https://doi.org/10.1016/j.synbio.2023.05.003
IF: 4.692
2023-06-05
Synthetic and Systems Biotechnology
Abstract:The bacterial trialkyl-substituted aromatic polyketides are structurally featured with the unusual aromatic core in the middle of polyketide chain such as TM-123 ( 1 ), veramycin A ( 2 ), NFAT-133 ( 3 ) and benwamycin I ( 4 ), which were discovered from Streptomyces species and demonstrated with antidiabetic and immunosuppressant activities. Though the biosynthetic pathway of 1 − 3 was reported as a type I polyketide synthase (PKS), the PKS assembly line was interpreted inconsistently, and it remains a mystery how the compound 3 was generated. Herein, the PKS assembly logic of 1 − 4 was revised by site-mutagenetic analysis of the PKS dehydratase domains. Based on gene deletion and complementation, the putative P450 monooxygenase nft E 1 and metallo-beta-lactamase (MBL) fold hydrolase nft F 1 were verified as essential genes for the biosynthesis of 1 − 4 . The absence of nft E 1 led to abolishment of 1 − 4 and accumulation of new products ( 5 − 8 ). Structural elucidation reveals 5 − 8 as the non-aromatic analogs of 1 , suggesting the NftE 1 -catalyzed aromatic core formation. Deletion of nft F 1 resulted in disappearance of 3 and 4 with the compounds 1 and 2 unaffected. As a rare MBL-fold hydrolase from type I PKSs, NftF 1 potentially generates the compound 3 through two strategies: catalyze premature chain-offloading as a trans -acting thioesterase or hydrolyze the lactone-bond of compound 1 as an esterase.
biotechnology & applied microbiology
What problem does this paper attempt to address?